Top Page
SRx Health Solutions
(NYSE MKT:SRXH)
SRx Health Solutions (SRXH) vs. SPDR S&P 500 ETF (SPY)
SRx Health Solutions Business Overview & Revenue Model
SRx Health Solutions Earnings Call Summary
SRx Health Solutions Financial Statement Overview
| Breakdown | TTM | Sep 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | -13.13M | 6.53M | 34.98M | 118.94M | 92.63M | 46.01M |
| Gross Profit | -2.64M | 1.50M | 12.86M | 23.61M | 13.31M | 13.70M |
| EBITDA | -37.15M | -11.50M | 438.00K | -7.05M | -539.40K | 8.30M |
| Net Income | -39.68M | -45.01M | -168.00K | -11.14M | -2.45M | 2.98M |
Balance Sheet | ||||||
| Total Assets | 27.05M | 8.40M | 15.80M | 64.51M | 34.79M | 77.42M |
| Cash, Cash Equivalents and Short-Term Investments | 13.06M | 1.83M | 3.07M | 2.07M | 1.66M | 28.94M |
| Total Debt | 21.03M | 6.24M | 45.31M | 39.38M | 17.85M | 10.33M |
| Total Liabilities | 23.53M | 8.00M | 7.15M | 70.80M | 33.86M | 19.55M |
| Stockholders Equity | 3.52M | 407.00K | -55.12M | -6.29M | 927.48K | 57.88M |
Cash Flow | ||||||
| Free Cash Flow | -11.06M | -11.00M | -4.40M | 1.58M | 3.13M | -12.21M |
| Operating Cash Flow | -11.06M | -11.00M | -4.36M | 2.85M | 3.38M | -11.86M |
| Investing Cash Flow | -2.56M | 5.91M | -2.25M | -19.78M | -6.83M | -353.00K |
| Financing Cash Flow | 30.96M | 12.17M | 5.22M | 16.43M | 3.80M | 37.16M |
SRx Health Solutions Technical Analysis
SRx Health Solutions Risk Analysis
SRx Health Solutions Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
56 Neutral | $6.28B | 14.03 | 7.56% | 1.56% | 9.45% | 167.00% | |
52 Neutral | $1.59B | 9.95 | 25.50% | 4.80% | -1.69% | -61.89% | |
45 Neutral | $55.20M | -3.95 | -55.19% | ― | ― | ― | |
43 Neutral | $38.14M | -0.22 | 435.85% | ― | -8.12% | ― |
SRx Health Solutions Corporate Events
On March 16, 2026, SRx Health Solutions entered into a Securities Purchase Agreement with accredited investors for a private placement of up to 10,000 shares of Series B convertible preferred stock and accompanying warrants, for potential gross proceeds of up to $8 million in one or more closings. At the initial closing on the same date, the company raised approximately $4.53 million in cash by issuing 5,660 Series B preferred shares and 22,237,666 warrants, with the warrants and conversion features set at an initial price of $0.3182 per share, subject to various adjustments after shareholder approval.
The newly designated Series B Preferred Stock carries a $1,000 stated value per share, ranks senior to common stock and pari passu with Series A preferred, offers as-converted dividends, and provides multiple conversion and redemption mechanisms tied to market prices and triggering events. The structure includes strict covenants limiting additional indebtedness, dividends, new preferred issuances, and certain fundamental transactions, and requires substantial share reservation and a registration rights agreement to facilitate resale, signaling both a near-term capital infusion and tighter contractual constraints that may affect equity holders and future financing flexibility.
The most recent analyst rating on (SRXH) stock is a Hold with a $0.14 price target. To see the full list of analyst forecasts on SRx Health Solutions stock, see the SRXH Stock Forecast page.
On July 7, 2025, SRx Health Solutions entered into a securities purchase agreement with accredited investors to issue $7.65 million in senior secured convertible notes and warrants for over 21.3 million common shares, followed by an October 27, 2025 agreement enabling up to $30.46 million of Series A convertible preferred stock and warrants. On October 31, 2025, the company closed a private placement of 19,035 Series A preferred shares and 54.5 million Series A warrants for proceeds of about $15.23 million, and now plans a new Series B preferred stock and warrant offering, supported by waivers from existing investors who are allowing the deal to proceed and consenting to Series B ranking pari passu with Series A on dividends and liquidation rights.
These waivers include the relinquishment of participation rights in the new and future placements, clearing structural and contractual obstacles to the Series B financing and reinforcing SRx Health Solutions’ flexibility to access additional capital. By securing investor consent for Series B to sit on equal footing with Series A in the capital structure, the company preserves preferred investor protections while broadening its funding options and potentially reshaping its long-term financing profile.
The most recent analyst rating on (SRXH) stock is a Sell with a $0.12 price target. To see the full list of analyst forecasts on SRx Health Solutions stock, see the SRXH Stock Forecast page.
On February 18, 2026, SRx Health Solutions received a public warning letter from NYSE Regulation stating it had violated Sections 301 and 713 of the NYSE American Company Guide. The breaches stemmed from issuing about 7.5 million common shares between December 31, 2025 and January 23, 2026 upon conversion of Series A preferred shares without proper listing approval or compliant shareholder authorization.
The exchange determined that SRx failed to obtain prior NYSE approval for the additional listed securities and that its written-consent shareholder approval was deficient under NYSE’s internal guidance on large share issuances. While all Series A preferred shares have since been converted or redeemed, the warning underscores the company’s noncompliance with continued listing requirements and signals that further violations could expose SRx to more severe regulatory actions, including potential delisting proceedings.
The most recent analyst rating on (SRXH) stock is a Hold with a $0.13 price target. To see the full list of analyst forecasts on SRx Health Solutions stock, see the SRXH Stock Forecast page.
On February 9, 2026, SRx Health Solutions notified holders of its Series A Convertible Preferred Stock that it would redeem all outstanding shares under the terms of its preferred stock designation. On February 11, 2026, the company completed the redemption of roughly 17,400–17,500 Series A Preferred shares for about $21.8 million, eliminating an instrument that had been issued in a $15.23 million private placement on October 31, 2025.
The transaction canceled the equivalent of approximately 125 million shares of common stock on an as-converted basis, significantly simplifying SRx Health’s capital structure. Management highlighted that the retirement of the preferred stock and related common shares improves balance sheet and capital structure flexibility, positioning the company to pursue future investments or potential capital returns to shareholders as opportunities arise, while it prepares to file its fiscal first-quarter Form 10-Q on February 13, 2026.
The most recent analyst rating on (SRXH) stock is a Sell with a $0.10 price target. To see the full list of analyst forecasts on SRx Health Solutions stock, see the SRXH Stock Forecast page.
On January 6, 2026, SRx Health Solutions, Inc., listed on the NYSE American under the symbol SRXH, received notice that the exchange had accepted its plan to regain compliance with continued listing standards related to minimum stockholders’ equity. The exchange had previously notified the company on October 14, 2025, that it was out of compliance after reporting negative stockholders’ equity of $45.9 million as of June 30, 2025 and losses in three of its four most recent fiscal years ended December 31, 2024. With the NYSE American’s acceptance of its remediation plan, SRx Health Solutions’ listing will continue under an extension through July 14, 2026, during which the company must execute its plan to restore equity levels, provide quarterly progress updates to the exchange, and seek to regain full compliance, a move that stabilizes its immediate listing status but underscores ongoing financial pressures and execution risk for shareholders and other stakeholders.
The most recent analyst rating on (SRXH) stock is a Hold with a $0.19 price target. To see the full list of analyst forecasts on SRx Health Solutions stock, see the SRXH Stock Forecast page.